To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.
Patients with colorectal liver metastases planned for resection
At least one tumor size >=3cm
Performance status 0-1
Liver cirrhosis
Extrahepatic metastases that can not be addressed curatively
Other malignant diseases within 5 years prior to diagnosis
Prior RFA treatment
Parallel
RFA (radiofrequency ablation)
DevicePreoperative RFA-induced partial necrosis of the liver metastasis
Overall survival
Median survival in each arm
One-year survival
One-year survival in each arm
Two-year survival
Two-year survival in each arm
Three-year survival
Three-year survival in each arm
Recurrence rate
Recurrence rate at 1, 2, and 3 years follow-up
Complications
Immediate postoperative complications (bleeding, surgical site infection, intraabdominal abscesses, bile leak)
Click on the lead sponsor to view all of their trials.
University of Aarhus
Lead sponsor
Aarhus University Hospital
Collaborator
Rigshospitalet, Denmark
Collaborator
